SlideShare une entreprise Scribd logo
1  sur  42
Télécharger pour lire hors ligne
What is EBM?

“The conscientious, explicit and judicious
  use of current best evidence in
  making decisions about the care of
  individual patients”

Prof. David L. Sackett, 1997
Why EBM?
Primum non nocere
 “First do no harm”

Hippocrates, Epidemics
Sources of Evidence in Medicine

• Traditional Teaching
• Textbooks
• Basic sciences
• Observational studies
• Computer simulation
• Decision Analysis
• Case-Control Studies
• Randomised Controlled Trials (RCT)
• Meta-analyses
RCOG Classification of Evidence Levels

1++ High quality meta-analyses of RCT's
1+ Meta-a. Or RCT's at low risk of bias
1- Meta-a. Or RCT's at high risk of bias
2++ High quality meta-analyses of CC's
2+ Well-conducted cc or cohort studies
2- Case-control or cohort studies with ? bias
3 Case reports
4 Expert opinion
Archie Cochrane (1909-88)

             “Effectiveness and
             Efficiency: Random
             Reflections of Health
             Services “, 1971
Randomized Controlled Trials


 “Gold standard” in evaluating new
 therapies or surgical techniques
 May also be applied to new diagnostic
 tests
Randomized Controlled Trials
Objectives of RCT:
   Minimize bias by randomisation
   Achieve statistical power through
   adequate sample size
   “Blinding “ - single or double
   Analysis by intention to treat
Randomized Controlled Trials

Randomisation
   Several techniques available
   Computer software linked to central
   monitoring station
   “Block “ randomisation
   Sealed envelope method
RCT’s and Observational Studies

• Two studies published in the NEJM in 2000 suggested that
RCTs and observational studies overall produced similar
results

• JAMA 2001: “discrepancies beyond chance do occur and
differences in estimated magnitude of treatment effect are
very common”

• RCTs may be unnecessary for treatments that have
dramatic and rapid effects relative to the expected
RCT’s and Industry Funding

•RCT’s funded by industry are significantly more likely to
report positive results

•Possibly due to publication bias

•RCTs may be unnecessary for treatments that have
dramatic and rapid effects relative to the expected
RCT’s and Statistical Error



• Type I error – “false positive”

• Type II error – “false negative”

• Sample size calculations often inaccurate
Diagnostic Tests
2 X 2 Table

            Disease   Disease
            present   absent
Test            a         b
Positive
Test            c         d
Negative
2 X 2 Table
           Disease   Disease
           present   absent
Test          a          b
Positive
Test          c          d
Negative



 Sensitivity = TP =
2 X 2 Table
           Disease   Disease
           present   absent
Test          a          b
Positive
Test          c          d
Negative

Sensitivity = TP = a/(a+c)
2 X 2 Table
            Disease   Disease
            present   absent
Test           a          b
Positive
Test           c          d
Negative



False Positive Rate = FP =
2 X 2 Table
            Disease   Disease
            present   absent
Test           a          b
Positive
Test           c          d
Negative


      FP = b/(d+b)
2 X 2 Table
              Disease   Disease
              present   absent
  Test           a          b
  Positive
  Test           c          d
  Negative


Specificity = 1 - FP =
2 X 2 Table
            Disease   Disease
            present   absent
 Test          a          b
 Positive
 Test          c          d
 Negative


Specificity = 1 - FP = d/(d+b)
2 X 2 Table
           Disease   Disease
           present   absent
Test          a          b
Positive
Test          c          d
Negative



Positive predictive value (PPV) =
2 X 2 Table
              Disease   Disease
              present   absent
  Test           a          b
  Positive
  Test           c          d
  Negative



PPV = a/(a+b)
2 X 2 Table
                 Disease   Disease
                 present   absent
      Test          a          b
      Positive
      Test          c          d
      Negative



Negative predictive value (NPV) =
2 X 2 Table
           Disease   Disease
           present   absent
Test          a          b
Positive
Test          c          d
Negative



           NPV = d/(c+d)
PPV and Prevalence



Steep drop in positive predictive
value as disease prevalence
decreases
The Likelihood Ratio

Single value to indicate the
clinical utility of a test
 Independent of prevalence
LR = Sensitivity/(1- Spec.)
LR >8 : tests usually clinically
useful
The Likelihood Ratio

LR is an odds modifier:

Posterior odds =
       prior odds x LR
Odds and Probability


   Inter-convertible:

   Odds = p/(1-p)
Can tests be combined ?


Rare conditions: high rates of
false positives
Lead to excessive unnecessary
intervention
Can be reduced by combining
tests e.g. intrapartum
monitoring
Impact of new diagnostic
test on clinical outcomes:


  RCT
  Cohort study
  Case-control study
  Before and after study
SYSTEMATIC REVIEWS
"It is surely a great criticism of our
  profession that we have not organised
  a critical summary, by specialty or
  subspecialty, adapted periodically, of
  all relevant randomized controlled
  trials."
           Archie Cochrane, 1972
Role of systematic reviews
Before commencing a new project: to determine
whether further studies are really indicated: ‘state-
of-the-art’ literature review.
Gain in statistical power for average estimates.
'Cumulative' meta-analysis can determine when
further studies are no longer indicated.
Design of subsequent studies.
Setting policy for treatment and health care –
making the best use of the data available.
Can Studies be Combined?

 Identification of optimal inclusion criteria can be
difficult.
 The most critical step is choosing the appropriate
research question.
 A fairly general question is more preferable to a very
specific one.
 Tukey : "...far better an approximate answer to the
right question, than an exact answer to the wrong
question.."
Publication Bias

Entire research studies may fail to reach publication
because of the nature of the results.

Identification of unpublished trials can be very
difficult - in one study it accounted for 22% of the
papers included in the meta-analysis.

 Failure to publish rests with the investigators rather
than editors.
PREDICTIVE ABILITY OF META-ANALYSES
         Villar et al, Lancet 1995

Comparison of the meta-analyses of smaller studies
with the corresponding result of the largest study.
 30 meta-analyses including a total of 185 randomised
controlled studies (RCT) obtained from the Cochrane
pregnancy and childbirth database. The meta-
analyses were only included if they had at least one
trial with a total sample size of over 1000.
 Calculations differ from the Cochrane database in
that the largest trial was excluded, this being used as
the 'gold standard' for outcome
The Cochrane Collaboration




 •   Established in 1993 by Sir Iain Chalmers
 •   International: 100 countries
 •   Independent
 •   Not-for-profit
 •   Over 27000 contributors
RANZCOG and EBM


“RANZCOG endorses the principles of Evidence-
based Medicine and recognizes the NHMRC levels of
evidence and grades of recommendations”

College Statement C-Gen 15, Nov. 2009
…a scientific idea can never be proven true,
because no matter how many observations seem to
agree with it, it may still be wrong. On the other
hand, a single contrary experiment can prove a
theory forever false


                               Sir Karl Popper

Contenu connexe

Tendances

VALIDITY AND RELIABLITY OF A SCREENING TEST seminar 2.pptx
VALIDITY AND RELIABLITY OF A SCREENING TEST seminar 2.pptxVALIDITY AND RELIABLITY OF A SCREENING TEST seminar 2.pptx
VALIDITY AND RELIABLITY OF A SCREENING TEST seminar 2.pptxShaliniPattanayak
 
Journal Club presentation in Nursing Research
Journal Club presentation in Nursing ResearchJournal Club presentation in Nursing Research
Journal Club presentation in Nursing ResearchDhara Vyas
 
Case control studies
Case control studiesCase control studies
Case control studieskeshavapavan
 
Case Control Studies
Case Control StudiesCase Control Studies
Case Control StudiesRachel Walden
 
Arab Board examination for Community Medicine.pdf
Arab Board examination for Community Medicine.pdfArab Board examination for Community Medicine.pdf
Arab Board examination for Community Medicine.pdfDr. AbdulQawi Almohamadi
 
Barriers to evidenced based practice Priyadarsini John
Barriers to evidenced based practice Priyadarsini JohnBarriers to evidenced based practice Priyadarsini John
Barriers to evidenced based practice Priyadarsini JohnPriya John
 
RCT Critical Appraisal - Results
RCT Critical Appraisal - ResultsRCT Critical Appraisal - Results
RCT Critical Appraisal - ResultsDr. Majdi Al Jasim
 
Hodgkins lymphoma history, physical exam and management
Hodgkins lymphoma history, physical exam and managementHodgkins lymphoma history, physical exam and management
Hodgkins lymphoma history, physical exam and managementLajpat Rai
 
Ospe (objective structured practical examination)
Ospe (objective structured practical examination)Ospe (objective structured practical examination)
Ospe (objective structured practical examination)Anisur Rahman
 
Study designs, Epidemiological study design, Types of studies
Study designs, Epidemiological study design, Types of studiesStudy designs, Epidemiological study design, Types of studies
Study designs, Epidemiological study design, Types of studiesDr Lipilekha Patnaik
 
Osce by c. shekhar karmakar
Osce by c. shekhar karmakarOsce by c. shekhar karmakar
Osce by c. shekhar karmakarChandra Karmakar
 
Translational epidemiology
Translational epidemiologyTranslational epidemiology
Translational epidemiologyBhoj Raj Singh
 
8. Acute Lymphoblastic Leukemia
8. Acute Lymphoblastic Leukemia8. Acute Lymphoblastic Leukemia
8. Acute Lymphoblastic LeukemiaWhiteraven68
 
Critical appraisal diagnostic
Critical appraisal diagnosticCritical appraisal diagnostic
Critical appraisal diagnosticAmir Mahmoud
 

Tendances (20)

VALIDITY AND RELIABLITY OF A SCREENING TEST seminar 2.pptx
VALIDITY AND RELIABLITY OF A SCREENING TEST seminar 2.pptxVALIDITY AND RELIABLITY OF A SCREENING TEST seminar 2.pptx
VALIDITY AND RELIABLITY OF A SCREENING TEST seminar 2.pptx
 
Journal Club presentation in Nursing Research
Journal Club presentation in Nursing ResearchJournal Club presentation in Nursing Research
Journal Club presentation in Nursing Research
 
Writing case report
Writing case reportWriting case report
Writing case report
 
OSCE & OSPE
OSCE & OSPEOSCE & OSPE
OSCE & OSPE
 
Case control studies
Case control studiesCase control studies
Case control studies
 
DNB OSCE SGRH - 2
DNB OSCE SGRH - 2DNB OSCE SGRH - 2
DNB OSCE SGRH - 2
 
Case Control Studies
Case Control StudiesCase Control Studies
Case Control Studies
 
Arab Board examination for Community Medicine.pdf
Arab Board examination for Community Medicine.pdfArab Board examination for Community Medicine.pdf
Arab Board examination for Community Medicine.pdf
 
Barriers to evidenced based practice Priyadarsini John
Barriers to evidenced based practice Priyadarsini JohnBarriers to evidenced based practice Priyadarsini John
Barriers to evidenced based practice Priyadarsini John
 
Confounder and effect modification
Confounder and effect modificationConfounder and effect modification
Confounder and effect modification
 
RCT Critical Appraisal - Results
RCT Critical Appraisal - ResultsRCT Critical Appraisal - Results
RCT Critical Appraisal - Results
 
OSCE - Pune mock OSCE 2012
OSCE - Pune mock OSCE 2012OSCE - Pune mock OSCE 2012
OSCE - Pune mock OSCE 2012
 
Hodgkins lymphoma history, physical exam and management
Hodgkins lymphoma history, physical exam and managementHodgkins lymphoma history, physical exam and management
Hodgkins lymphoma history, physical exam and management
 
Ospe (objective structured practical examination)
Ospe (objective structured practical examination)Ospe (objective structured practical examination)
Ospe (objective structured practical examination)
 
Study designs, Epidemiological study design, Types of studies
Study designs, Epidemiological study design, Types of studiesStudy designs, Epidemiological study design, Types of studies
Study designs, Epidemiological study design, Types of studies
 
Osce by c. shekhar karmakar
Osce by c. shekhar karmakarOsce by c. shekhar karmakar
Osce by c. shekhar karmakar
 
Translational epidemiology
Translational epidemiologyTranslational epidemiology
Translational epidemiology
 
8. Acute Lymphoblastic Leukemia
8. Acute Lymphoblastic Leukemia8. Acute Lymphoblastic Leukemia
8. Acute Lymphoblastic Leukemia
 
Critical appraisal diagnostic
Critical appraisal diagnosticCritical appraisal diagnostic
Critical appraisal diagnostic
 
Research methodology
Research methodologyResearch methodology
Research methodology
 

Similaire à The ABC of Evidence-Based Medicine

Tests of diagnostic accuracy
Tests of diagnostic accuracyTests of diagnostic accuracy
Tests of diagnostic accuracySimba Takuva
 
Epidemiological Approaches for Evaluation of diagnostic tests.pptx
Epidemiological Approaches for Evaluation of diagnostic tests.pptxEpidemiological Approaches for Evaluation of diagnostic tests.pptx
Epidemiological Approaches for Evaluation of diagnostic tests.pptxBhoj Raj Singh
 
Study design used in pharmacoepidemiology
Study design used in pharmacoepidemiology Study design used in pharmacoepidemiology
Study design used in pharmacoepidemiology kamolwantnok
 
Basic Stats for the FRCS (Urol) Exam
Basic Stats for the FRCS (Urol) ExamBasic Stats for the FRCS (Urol) Exam
Basic Stats for the FRCS (Urol) ExamDrNikhilVasdev
 
Economic evaluation, reimbursement and context. How to assess personalised me...
Economic evaluation, reimbursement and context. How to assess personalised me...Economic evaluation, reimbursement and context. How to assess personalised me...
Economic evaluation, reimbursement and context. How to assess personalised me...HTAi Bilbao 2012
 
1559221358_week 6-MCQ in EBP-1.pdf
1559221358_week 6-MCQ in EBP-1.pdf1559221358_week 6-MCQ in EBP-1.pdf
1559221358_week 6-MCQ in EBP-1.pdfSajidaCheema1
 
Probability.pdf.pdf and Statistics for R
Probability.pdf.pdf and Statistics for RProbability.pdf.pdf and Statistics for R
Probability.pdf.pdf and Statistics for RSakhileKhoza2
 
Public Health for Pre-Health Professionals
Public Health for Pre-Health ProfessionalsPublic Health for Pre-Health Professionals
Public Health for Pre-Health ProfessionalsNicholas Mercado
 
Disease screening and screening test validity
Disease screening and screening test validityDisease screening and screening test validity
Disease screening and screening test validityTampiwaChebani
 
session three epidemiology.pptx
session three epidemiology.pptxsession three epidemiology.pptx
session three epidemiology.pptxAxmedAbdiHasen
 
session three epidemiology.pptx
session three epidemiology.pptxsession three epidemiology.pptx
session three epidemiology.pptxAxmedAbdiHasen
 
Advance concept of screening_Nabaraj Paudel
Advance concept of screening_Nabaraj PaudelAdvance concept of screening_Nabaraj Paudel
Advance concept of screening_Nabaraj PaudelNabaraj Paudel
 
Validity of a screening test
Validity of a screening testValidity of a screening test
Validity of a screening testdrkulrajat
 
Eugm 2012 unknown - incivex drug development process overview road to findi...
Eugm 2012   unknown - incivex drug development process overview road to findi...Eugm 2012   unknown - incivex drug development process overview road to findi...
Eugm 2012 unknown - incivex drug development process overview road to findi...Cytel USA
 
Rare Solid Cancers: An Introduction - Slide 3 - P. Bruzzi - Methodological as...
Rare Solid Cancers: An Introduction - Slide 3 - P. Bruzzi - Methodological as...Rare Solid Cancers: An Introduction - Slide 3 - P. Bruzzi - Methodological as...
Rare Solid Cancers: An Introduction - Slide 3 - P. Bruzzi - Methodological as...European School of Oncology
 

Similaire à The ABC of Evidence-Based Medicine (20)

Screening
ScreeningScreening
Screening
 
Tests of diagnostic accuracy
Tests of diagnostic accuracyTests of diagnostic accuracy
Tests of diagnostic accuracy
 
Epidemiological Approaches for Evaluation of diagnostic tests.pptx
Epidemiological Approaches for Evaluation of diagnostic tests.pptxEpidemiological Approaches for Evaluation of diagnostic tests.pptx
Epidemiological Approaches for Evaluation of diagnostic tests.pptx
 
Study design used in pharmacoepidemiology
Study design used in pharmacoepidemiology Study design used in pharmacoepidemiology
Study design used in pharmacoepidemiology
 
Basic Stats for the FRCS (Urol) Exam
Basic Stats for the FRCS (Urol) ExamBasic Stats for the FRCS (Urol) Exam
Basic Stats for the FRCS (Urol) Exam
 
Economic evaluation, reimbursement and context. How to assess personalised me...
Economic evaluation, reimbursement and context. How to assess personalised me...Economic evaluation, reimbursement and context. How to assess personalised me...
Economic evaluation, reimbursement and context. How to assess personalised me...
 
05 diagnostic tests cwq
05 diagnostic tests cwq05 diagnostic tests cwq
05 diagnostic tests cwq
 
1559221358_week 6-MCQ in EBP-1.pdf
1559221358_week 6-MCQ in EBP-1.pdf1559221358_week 6-MCQ in EBP-1.pdf
1559221358_week 6-MCQ in EBP-1.pdf
 
Probability.pdf.pdf and Statistics for R
Probability.pdf.pdf and Statistics for RProbability.pdf.pdf and Statistics for R
Probability.pdf.pdf and Statistics for R
 
Screening
ScreeningScreening
Screening
 
Public Health for Pre-Health Professionals
Public Health for Pre-Health ProfessionalsPublic Health for Pre-Health Professionals
Public Health for Pre-Health Professionals
 
Evidence Based Diagnosis
Evidence Based DiagnosisEvidence Based Diagnosis
Evidence Based Diagnosis
 
Disease screening and screening test validity
Disease screening and screening test validityDisease screening and screening test validity
Disease screening and screening test validity
 
Dr swe swe latt screening for slideshare
Dr swe swe latt screening for slideshareDr swe swe latt screening for slideshare
Dr swe swe latt screening for slideshare
 
session three epidemiology.pptx
session three epidemiology.pptxsession three epidemiology.pptx
session three epidemiology.pptx
 
session three epidemiology.pptx
session three epidemiology.pptxsession three epidemiology.pptx
session three epidemiology.pptx
 
Advance concept of screening_Nabaraj Paudel
Advance concept of screening_Nabaraj PaudelAdvance concept of screening_Nabaraj Paudel
Advance concept of screening_Nabaraj Paudel
 
Validity of a screening test
Validity of a screening testValidity of a screening test
Validity of a screening test
 
Eugm 2012 unknown - incivex drug development process overview road to findi...
Eugm 2012   unknown - incivex drug development process overview road to findi...Eugm 2012   unknown - incivex drug development process overview road to findi...
Eugm 2012 unknown - incivex drug development process overview road to findi...
 
Rare Solid Cancers: An Introduction - Slide 3 - P. Bruzzi - Methodological as...
Rare Solid Cancers: An Introduction - Slide 3 - P. Bruzzi - Methodological as...Rare Solid Cancers: An Introduction - Slide 3 - P. Bruzzi - Methodological as...
Rare Solid Cancers: An Introduction - Slide 3 - P. Bruzzi - Methodological as...
 

Dernier

Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best supplerCas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best supplerSherrylee83
 
ROSE CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
ROSE  CASE SPINAL SBRT BY DR KANHU CHARAN PATROROSE  CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
ROSE CASE SPINAL SBRT BY DR KANHU CHARAN PATROKanhu Charan
 
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...marcuskenyatta275
 
Introducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European UnionIntroducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European UnionGolden Helix
 
Dermatome and myotome test & pathology.pdf
Dermatome and myotome test & pathology.pdfDermatome and myotome test & pathology.pdf
Dermatome and myotome test & pathology.pdfniloofarbarzegari76
 
Gallbladder Double-Diverticular: A Case Report المرارة مزدوجة التج: تقرير حالة
Gallbladder Double-Diverticular: A Case Report  المرارة مزدوجة التج: تقرير حالةGallbladder Double-Diverticular: A Case Report  المرارة مزدوجة التج: تقرير حالة
Gallbladder Double-Diverticular: A Case Report المرارة مزدوجة التج: تقرير حالةMohamad محمد Al-Gailani الكيلاني
 
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale nowSherrylee83
 
Circulation through Special Regions -characteristics and regulation
Circulation through Special Regions -characteristics and regulationCirculation through Special Regions -characteristics and regulation
Circulation through Special Regions -characteristics and regulationMedicoseAcademics
 
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptx
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptxSURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptx
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptxSuresh Kumar K
 
TEST BANK for The Nursing Assistant Acute, Subacute, and Long-Term Care, 6th ...
TEST BANK for The Nursing Assistant Acute, Subacute, and Long-Term Care, 6th ...TEST BANK for The Nursing Assistant Acute, Subacute, and Long-Term Care, 6th ...
TEST BANK for The Nursing Assistant Acute, Subacute, and Long-Term Care, 6th ...marcuskenyatta275
 
Case presentation on Antibody screening- how to solve 3 cell and 11 cell panel?
Case presentation on Antibody screening- how to solve 3 cell and 11 cell panel?Case presentation on Antibody screening- how to solve 3 cell and 11 cell panel?
Case presentation on Antibody screening- how to solve 3 cell and 11 cell panel?DrShinyKajal
 
Failure to thrive in neonates and infants + pediatric case.pptx
Failure to thrive in neonates and infants  + pediatric case.pptxFailure to thrive in neonates and infants  + pediatric case.pptx
Failure to thrive in neonates and infants + pediatric case.pptxclaviclebrown44
 
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...PhRMA
 
Factors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric DentistryFactors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric DentistryDr Simran Deepak Vangani
 
5cladba raw material 5CL-ADB-A precursor raw
5cladba raw material 5CL-ADB-A precursor raw5cladba raw material 5CL-ADB-A precursor raw
5cladba raw material 5CL-ADB-A precursor rawSherrylee83
 
CT scan of penetrating abdominopelvic trauma
CT scan of penetrating abdominopelvic traumaCT scan of penetrating abdominopelvic trauma
CT scan of penetrating abdominopelvic traumassuser144901
 
World Hypertension Day 17th may 2024 ppt
World Hypertension Day 17th may 2024 pptWorld Hypertension Day 17th may 2024 ppt
World Hypertension Day 17th may 2024 pptdesktoppc
 
Sonia Journal club presentation (2).pptx
Sonia Journal club presentation (2).pptxSonia Journal club presentation (2).pptx
Sonia Journal club presentation (2).pptxpalsonia139
 
Renal Replacement Therapy in Acute Kidney Injury -time modality -Dr Ayman Se...
Renal Replacement Therapy in Acute Kidney Injury -time  modality -Dr Ayman Se...Renal Replacement Therapy in Acute Kidney Injury -time  modality -Dr Ayman Se...
Renal Replacement Therapy in Acute Kidney Injury -time modality -Dr Ayman Se...Ayman Seddik
 

Dernier (20)

Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best supplerCas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
 
ROSE CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
ROSE  CASE SPINAL SBRT BY DR KANHU CHARAN PATROROSE  CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
ROSE CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
 
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
TEST BANK For Huether and McCance's Understanding Pathophysiology, Canadian 2...
 
Introducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European UnionIntroducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European Union
 
Dermatome and myotome test & pathology.pdf
Dermatome and myotome test & pathology.pdfDermatome and myotome test & pathology.pdf
Dermatome and myotome test & pathology.pdf
 
Gallbladder Double-Diverticular: A Case Report المرارة مزدوجة التج: تقرير حالة
Gallbladder Double-Diverticular: A Case Report  المرارة مزدوجة التج: تقرير حالةGallbladder Double-Diverticular: A Case Report  المرارة مزدوجة التج: تقرير حالة
Gallbladder Double-Diverticular: A Case Report المرارة مزدوجة التج: تقرير حالة
 
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
 
Circulation through Special Regions -characteristics and regulation
Circulation through Special Regions -characteristics and regulationCirculation through Special Regions -characteristics and regulation
Circulation through Special Regions -characteristics and regulation
 
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptx
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptxSURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptx
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptx
 
TEST BANK for The Nursing Assistant Acute, Subacute, and Long-Term Care, 6th ...
TEST BANK for The Nursing Assistant Acute, Subacute, and Long-Term Care, 6th ...TEST BANK for The Nursing Assistant Acute, Subacute, and Long-Term Care, 6th ...
TEST BANK for The Nursing Assistant Acute, Subacute, and Long-Term Care, 6th ...
 
Case presentation on Antibody screening- how to solve 3 cell and 11 cell panel?
Case presentation on Antibody screening- how to solve 3 cell and 11 cell panel?Case presentation on Antibody screening- how to solve 3 cell and 11 cell panel?
Case presentation on Antibody screening- how to solve 3 cell and 11 cell panel?
 
Failure to thrive in neonates and infants + pediatric case.pptx
Failure to thrive in neonates and infants  + pediatric case.pptxFailure to thrive in neonates and infants  + pediatric case.pptx
Failure to thrive in neonates and infants + pediatric case.pptx
 
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
 
Factors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric DentistryFactors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric Dentistry
 
5cladba raw material 5CL-ADB-A precursor raw
5cladba raw material 5CL-ADB-A precursor raw5cladba raw material 5CL-ADB-A precursor raw
5cladba raw material 5CL-ADB-A precursor raw
 
CT scan of penetrating abdominopelvic trauma
CT scan of penetrating abdominopelvic traumaCT scan of penetrating abdominopelvic trauma
CT scan of penetrating abdominopelvic trauma
 
World Hypertension Day 17th may 2024 ppt
World Hypertension Day 17th may 2024 pptWorld Hypertension Day 17th may 2024 ppt
World Hypertension Day 17th may 2024 ppt
 
Sonia Journal club presentation (2).pptx
Sonia Journal club presentation (2).pptxSonia Journal club presentation (2).pptx
Sonia Journal club presentation (2).pptx
 
HyperIgE syndrome: primary immune deficiency.pdf
HyperIgE syndrome: primary immune deficiency.pdfHyperIgE syndrome: primary immune deficiency.pdf
HyperIgE syndrome: primary immune deficiency.pdf
 
Renal Replacement Therapy in Acute Kidney Injury -time modality -Dr Ayman Se...
Renal Replacement Therapy in Acute Kidney Injury -time  modality -Dr Ayman Se...Renal Replacement Therapy in Acute Kidney Injury -time  modality -Dr Ayman Se...
Renal Replacement Therapy in Acute Kidney Injury -time modality -Dr Ayman Se...
 

The ABC of Evidence-Based Medicine

  • 1.
  • 2. What is EBM? “The conscientious, explicit and judicious use of current best evidence in making decisions about the care of individual patients” Prof. David L. Sackett, 1997
  • 4. Primum non nocere “First do no harm” Hippocrates, Epidemics
  • 5. Sources of Evidence in Medicine • Traditional Teaching • Textbooks • Basic sciences • Observational studies • Computer simulation • Decision Analysis • Case-Control Studies • Randomised Controlled Trials (RCT) • Meta-analyses
  • 6. RCOG Classification of Evidence Levels 1++ High quality meta-analyses of RCT's 1+ Meta-a. Or RCT's at low risk of bias 1- Meta-a. Or RCT's at high risk of bias 2++ High quality meta-analyses of CC's 2+ Well-conducted cc or cohort studies 2- Case-control or cohort studies with ? bias 3 Case reports 4 Expert opinion
  • 7. Archie Cochrane (1909-88) “Effectiveness and Efficiency: Random Reflections of Health Services “, 1971
  • 8. Randomized Controlled Trials “Gold standard” in evaluating new therapies or surgical techniques May also be applied to new diagnostic tests
  • 9. Randomized Controlled Trials Objectives of RCT: Minimize bias by randomisation Achieve statistical power through adequate sample size “Blinding “ - single or double Analysis by intention to treat
  • 10. Randomized Controlled Trials Randomisation Several techniques available Computer software linked to central monitoring station “Block “ randomisation Sealed envelope method
  • 11.
  • 12. RCT’s and Observational Studies • Two studies published in the NEJM in 2000 suggested that RCTs and observational studies overall produced similar results • JAMA 2001: “discrepancies beyond chance do occur and differences in estimated magnitude of treatment effect are very common” • RCTs may be unnecessary for treatments that have dramatic and rapid effects relative to the expected
  • 13. RCT’s and Industry Funding •RCT’s funded by industry are significantly more likely to report positive results •Possibly due to publication bias •RCTs may be unnecessary for treatments that have dramatic and rapid effects relative to the expected
  • 14. RCT’s and Statistical Error • Type I error – “false positive” • Type II error – “false negative” • Sample size calculations often inaccurate
  • 16. 2 X 2 Table Disease Disease present absent Test a b Positive Test c d Negative
  • 17. 2 X 2 Table Disease Disease present absent Test a b Positive Test c d Negative Sensitivity = TP =
  • 18. 2 X 2 Table Disease Disease present absent Test a b Positive Test c d Negative Sensitivity = TP = a/(a+c)
  • 19. 2 X 2 Table Disease Disease present absent Test a b Positive Test c d Negative False Positive Rate = FP =
  • 20. 2 X 2 Table Disease Disease present absent Test a b Positive Test c d Negative FP = b/(d+b)
  • 21. 2 X 2 Table Disease Disease present absent Test a b Positive Test c d Negative Specificity = 1 - FP =
  • 22. 2 X 2 Table Disease Disease present absent Test a b Positive Test c d Negative Specificity = 1 - FP = d/(d+b)
  • 23. 2 X 2 Table Disease Disease present absent Test a b Positive Test c d Negative Positive predictive value (PPV) =
  • 24. 2 X 2 Table Disease Disease present absent Test a b Positive Test c d Negative PPV = a/(a+b)
  • 25. 2 X 2 Table Disease Disease present absent Test a b Positive Test c d Negative Negative predictive value (NPV) =
  • 26. 2 X 2 Table Disease Disease present absent Test a b Positive Test c d Negative NPV = d/(c+d)
  • 27. PPV and Prevalence Steep drop in positive predictive value as disease prevalence decreases
  • 28. The Likelihood Ratio Single value to indicate the clinical utility of a test Independent of prevalence LR = Sensitivity/(1- Spec.) LR >8 : tests usually clinically useful
  • 29. The Likelihood Ratio LR is an odds modifier: Posterior odds = prior odds x LR
  • 30. Odds and Probability Inter-convertible: Odds = p/(1-p)
  • 31. Can tests be combined ? Rare conditions: high rates of false positives Lead to excessive unnecessary intervention Can be reduced by combining tests e.g. intrapartum monitoring
  • 32. Impact of new diagnostic test on clinical outcomes: RCT Cohort study Case-control study Before and after study
  • 34. "It is surely a great criticism of our profession that we have not organised a critical summary, by specialty or subspecialty, adapted periodically, of all relevant randomized controlled trials." Archie Cochrane, 1972
  • 35. Role of systematic reviews Before commencing a new project: to determine whether further studies are really indicated: ‘state- of-the-art’ literature review. Gain in statistical power for average estimates. 'Cumulative' meta-analysis can determine when further studies are no longer indicated. Design of subsequent studies. Setting policy for treatment and health care – making the best use of the data available.
  • 36. Can Studies be Combined? Identification of optimal inclusion criteria can be difficult. The most critical step is choosing the appropriate research question. A fairly general question is more preferable to a very specific one. Tukey : "...far better an approximate answer to the right question, than an exact answer to the wrong question.."
  • 37. Publication Bias Entire research studies may fail to reach publication because of the nature of the results. Identification of unpublished trials can be very difficult - in one study it accounted for 22% of the papers included in the meta-analysis. Failure to publish rests with the investigators rather than editors.
  • 38. PREDICTIVE ABILITY OF META-ANALYSES Villar et al, Lancet 1995 Comparison of the meta-analyses of smaller studies with the corresponding result of the largest study. 30 meta-analyses including a total of 185 randomised controlled studies (RCT) obtained from the Cochrane pregnancy and childbirth database. The meta- analyses were only included if they had at least one trial with a total sample size of over 1000. Calculations differ from the Cochrane database in that the largest trial was excluded, this being used as the 'gold standard' for outcome
  • 39.
  • 40. The Cochrane Collaboration • Established in 1993 by Sir Iain Chalmers • International: 100 countries • Independent • Not-for-profit • Over 27000 contributors
  • 41. RANZCOG and EBM “RANZCOG endorses the principles of Evidence- based Medicine and recognizes the NHMRC levels of evidence and grades of recommendations” College Statement C-Gen 15, Nov. 2009
  • 42. …a scientific idea can never be proven true, because no matter how many observations seem to agree with it, it may still be wrong. On the other hand, a single contrary experiment can prove a theory forever false Sir Karl Popper